Related Experiment Video
Updated: May 9, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Cyclooxygenase-2 genetic polymorphism and stroke subtypes in Chinese
Guo-zhong Chen1, Xiao-yun Shan, Gan-ping Cheng
1Tongde Hospital of Zhejiang Province, Hangzhou, 311122, Zhejiang Province, People's Republic of China.
Journal of Molecular Neuroscience : MN
|August 3, 2013
Summary
The cyclooxygenase-2 (COX-2) -1195G>A gene polymorphism and A-1195-G-765 haplotype are linked to increased ischemic stroke risk, particularly small vessel occlusion (SVO), in the Chinese population.
Area of Science:
- Genetics
- Neurology
- Cardiovascular Research
Background:
- Cyclooxygenase-2 (COX-2) plays a role in inflammation associated with atherosclerosis.
- Investigating genetic variations in COX-2 is crucial for understanding stroke pathogenesis.
Purpose of the Study:
- To examine the association between COX-2 gene polymorphisms (-1195G>A and -765G>C) and ischemic stroke subtypes in a Chinese population.
- To determine if specific COX-2 genetic variants influence susceptibility to large artery atherosclerosis (LAA) or small vessel occlusion (SVO).
Main Methods:
- Genotyping of 224 LAA patients, 329 SVO patients, and 450 controls for COX-2 -1195G>A (rs689466) and -765G>C (rs20417) polymorphisms.
- Utilizing polymerase chain reaction-restriction fragment length polymorphism for genotyping.
- Applying chi-square tests and logistic regression for association and linkage disequilibrium analyses.
Main Results:
- The -1195G>A polymorphism was significantly associated with an increased risk of ischemic stroke (OR=1.51) and SVO (OR=1.57).
- The A-1195-G-765 haplotype also showed a significant association with higher risks of ischemic stroke (OR=1.27) and SVO (OR=1.27).
- No significant association was found between the -765G>C polymorphism and ischemic stroke risk, nor between the 1195G>A polymorphism and LAA.
Conclusions:
- The COX-2 -1195G>A polymorphism and the A-1195-G-765 haplotype are associated with ischemic stroke susceptibility in the Chinese population.
- These genetic associations appear specific to small vessel occlusion (SVO) rather than large artery atherosclerosis (LAA).
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Stroke: Introduction and Types
A stroke is an acute neurological event caused by the sudden disruption of cerebral blood flow, leading to rapid loss of neuronal function. Neurons depend on continuous oxygen and glucose supply, so even brief interruptions can cause irreversible injury within minutes. Strokes are classified into ischemic and hemorrhagic types.Ischemic StrokeIschemic strokes are most common and occur due to arterial occlusion, depriving brain tissue of oxygen and nutrients. This leads to energy failure, ionic...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...